A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 33
- Registration Number
- NCT04941989
- Locations
- π¬π§
Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom
Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 15
- Registration Number
- NCT04935320
- Locations
- π¬π§
Hammersmith Medicines Research Ltd (HMR), London, United Kingdom
Measurement of HTL0016878 in Cerebrospinal Fluid
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 16
- Registration Number
- NCT04849286
- Locations
- π¬π§
MAC Clinical Research, Manchester, United Kingdom
Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 8
- Registration Number
- NCT04462263
- Locations
- π¬π§
Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 42
- Registration Number
- NCT03847207
- Locations
- π¬π§
Quotient Sciences, Nottingham, United Kingdom
Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 71
- Registration Number
- NCT03785054
- Locations
- π¬π§
Covance, Leeds, West Yorkshire, United Kingdom
A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Heptares Therapeutics Limited
- Registration Number
- NCT03592862
- Locations
- π―π΅
Kagawa Prefectural Central Hospital, Takamatsu, Japan
π―π΅Nishitaga Hospital, Sendai, Japan
π―π΅Kurumi Clinic, Tokyo, Japan
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 60
- Registration Number
- NCT03456349
- Locations
- πͺπΈ
Syneos, Barcelona, Spain
A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 120
- Registration Number
- NCT03244228
- Locations
- π¬π§
Hammersmith Medicines Research, London, Hammersmith, United Kingdom
Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 54
- Registration Number
- NCT03198624
- Locations
- π¬π§
Richmond Pharmacology, London, London Bridge, United Kingdom
Β© Copyright 2024. All Rights Reserved by MedPath